Table III. HLA-C*07:01 transgenic mice have CD8+ T cell responses against HLA-C*07:01–binding peptides of high stability
Peptide SequenceHLA-C*07:01–Binding PredictionpHLA-I Stability, t1/2 (h)References
NetMHCpanPSCPL ScorebCD8+ T Cell IFN-γ Responses (INF-γ/106 Cells)
% RankaBinding LevelDNA ImmunizationPeptide Immunization
PLADLSPFA50.00Nonbinder0ND0/0/0/00/0/0/0(26, 35)
EGDCAPEEK50.00Nonbinder0ND0/0/0/00/0/0/0(26, 36)
RNGYRALMDKS50.00NonbinderN/AcND0/0/0/00/0/0/0(26, 37)
RRRPVTRPL0.12Strong binder8516.233/33/24/1619/599/177/0(26)
RRARYWLTY0.30Strong binder8127.2273/246/42/9643/640/133/97/92(26)
RRMATTFTF0.12Strong binder26734.6338/185/125/101317/225/69/21/0
RRNDGVVQY0.25Strong binder9916.317/0/0/0308/289/189/50/34
RYSGFVRTL0.25Strong binder5017.7427/371/56/5388/185/7/5
SRPLVSFSF1.50Weak binder4022.4329/318/20/3221/123/49/38
  • Predicted HLA-C*07:01–binding peptides of high stability and previously published HLA-C*07:01–restricted peptides were used to immunize HLA-C*07:01 transgenic mice. IFN-γ T cell responses were assayed by ELISPOT following peptide and DNA immunization. Peptide-binding predictions were done using the updated NetMHCpan server, and PSCPL scores were calculated by multiplication of the individual RB value from each peptide position using the PSCPL-derived HLA-C*07:01–binding matrix. The peptides reported were selected from a large repository of peptides collected for many different purposes. The pHLA-I complex stability was measured by an SPA-based pMHC-I dissociation assay. ND, not determined.

  • a Values of <0.5 are considered high-affinity interactions, 0.5–2 medium-affinity interaction, and values of >2 are considered of low affinity or nonbinding.

  • b PSCPL scores are calculated by multiplication of the PSCPL-derived RB value for each peptide position (see Materials and Methods); higher values predict higher affinity.

  • c Not available. PSCPL prediction scores are based on a nonamer PSCPL and can thus only be calculated for nonameric peptides.